Company news
Xeris Biopharma Holdings, Inc. news in 2021
Xeris Biopharma Holdings, Inc.'s news releases, calls and decks from 2021, newest first.
Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
December 29, 2021
Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma
December 15, 2021
Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights
November 9, 2021
Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021
November 1, 2021
Xeris Pharmaceuticals Enters Collaboration Agreement With Merck
October 24, 2021
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
October 4, 2021
Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 16, 2021
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
September 13, 2021
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.
September 7, 2021
Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 6, 2021
Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)
August 31, 2021
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
August 30, 2021
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma
August 29, 2021
Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia
August 22, 2021
Xeris Pharmaceuticals Strengthens Its Patent Estate
August 18, 2021
Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®
August 12, 2021
Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism
August 10, 2021
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
August 4, 2021
Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
July 28, 2021
Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
July 28, 2021
Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success
July 27, 2021
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe
July 18, 2021
Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
May 23, 2021
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
May 23, 2021
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
May 23, 2021
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
May 12, 2021
Xeris Pharmaceuticals to Webcast Upcoming Presentations
May 9, 2021
Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
May 5, 2021
Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank
May 5, 2021
Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
April 28, 2021
Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering
March 10, 2021
Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights
March 8, 2021
Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on March 9, 2021
March 1, 2021
Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations
February 17, 2021
Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
February 11, 2021
Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
January 4, 2021